Apolipoprotein A-V (apoA-V) was discovered by comparative genomic analysis of human and murine DNA and by a cDNA subtraction approach in the rat (1). In murine models and human subjects, strong correlations of apoA-V expression levels and DNA sequence polymorphisms, respectively, with plasma triglyceride (TG) levels have been observed (2; reviewed in Ref. 3). In the rat, hepatic apoA-V expression is induced significantly after partial hepatectomy (1). The effects of genetically manipulating murine apoA-V underscore the importance of this exchangeable apolipoprotein (4) in the maintenance of normal TG levels: overexpressing mice are hypotriglyceremic, and knockout mice are hypertriglyceremic (2). However, in contrast to results in animal studies, human plasma apoA-V positively correlates with plasma TG levels (5), and APOAV may thus define a TG-modifier gene (6).

Despite many recent studies, the apoA-V activity responsible for the effects on TG levels and metabolic events remains unclear. As discussed previously (7), possible functions include proteoglycan-dependent direct modulation of LPL activity, interference with the secretion of nascent TG-rich lipoproteins, and/or indirect effects on lipolysis via apoA-V binding to heparan sulfate proteoglycans. Another possibility for the action of apoA-V has been indicated by the finding (8) that VLDL particles from apoA-V mice are poorer competitors for binding to the LDL receptor than those from normal mice, implying a possible role for apoA-V in mediating or modulating lipoprotein receptor binding. This mode of action is supported by a report (9) that appeared during the revision of this article. By surface plasmon resonance measurements, the authors demonstrated the interaction of human recombinant apoA-V with two membrane receptors, the LDL receptor-related protein (10) and the mosaic receptor SorLA/LR11 (11).

Studies in nonmammalian species can reveal novel aspects of apoA-V biology. We and others are exploiting the laying hen to answer questions concerning key components of lipoprotein metabolism. Studies have focused on the molecular genetics of endocytic receptors belonging to the low density lipoprotein receptor gene family in oocytes and somatic cells (12), lipoprotein-modifying enzymes (13), follicular lipoprotein transport (14), and apolipoproteins (15, 16). For instance, a study in the chicken indicated that the enzymatic activity of LCAT was not dependent on cysteine residues at positions 31 and 184, as the active avian enzyme contains phenylalanine and asparagine, respectively, in the corresponding positions (13). Another example of the model’s power was the demonstration of a mutation in ABCA1 as the cause for severe HDL deficiency in the Wisconsin hypoalpha mutant chicken strain (17), which is the only known naturally occurring animal model for Tangier disease. Finally, as
The delineation of apolipoprotein function, chicken apoVLDL-II has been identified as a prototype LPL inhibitor (18).

The chicken APOAI and APOA4 genes are located in a cluster on chicken chromosome 24. To our knowledge, the exact primary structure of galline apoA-V has not yet been determined, nor has an APOC3 locus been unambiguously identified in the chicken to date. Here, we show that i) chickens do synthesize the protein encoded by the avian APOA5 gene (i.e., ggapoA-V); ii) ggapoA-V is detectable in the circulation; and iii) chicken apoA-V interacts with a prominent member of the avian LDL receptor gene family, as determined by direct ligand blotting methodology.

MATERIALS AND METHODS

Animals

Mature Derco-Brown hens (30–40 weeks old) were purchased from Heindl Co. (Vienna, Austria). All animals were maintained on layer’s mash with free access to water and feed and with a daily light period of 14 h.

Protein expression and antibodies

A 984 bp cDNA fragment encoding full-length chicken apoA-V (ggapoA-V) lacking the 23 residue signal peptide (Fig. 1) was cloned into the pET25b+ expression vector (Novagen), providing a C-terminal His6 tag. The primers were as follows: forward, 5'-ATCCATGGAGTTGCTTCTGGGAG-3' (NdeI site in boldface); and reverse, 5'-AAGATTCCGTGCGGATCCCGCGCCGCG-3' (EcoRI site in boldface). Recombinant ggapoA-V was expressed in BL21 cells (Invitrogen) and purified under native conditions using nickel-nitrilotriacetic acid agarose (Qiagen). Expression and purification were performed according to the protocol from Qiagen. Antiserum against recombinant ggapoA-V was raised in adult female New Zealand White rabbits by injections of 250 μg each of antigen as described previously (14). Murine monoclonal Penta-His antibody (Qiagen; used at 1:500) and mouse anti-glutathione S-transferase (GST) antibody (BD Pharming; used at 1:2,000) were purchased from the indicated sources. Rabbit anti-LR8 IgG was prepared as described previously (19). Recombinant GST-receptor-associated protein (RAP) fusion protein was produced in DH5 bac-

![Fig. 1. Alignment of the amino acid sequences of apolipoprotein A-V (apoA-V) from human (Hs), chicken (Gg), and mouse (Mm). Identical residues are boxed in dark gray, and conservative substitutions are boxed in light gray. The predicted signal cleavage site in the apoA-V precursor molecules is indicated by an open arrowhead. Numbering starts with the initiator methionine, 23 residues upstream of the signal sequence cleavage site.](image-url)
teria using a PGEX 2T-derived (Pharmacia) expression plasmid (20).

Preparation of tissue and membrane protein extracts

All operations were performed at 4°C. For total protein extracts, fresh chicken tissues were homogenized (5 ml/g wet tissue) with an Ultra-Turrax T25 homogenizer in buffer containing 20 mM HEPES (pH 7.4), 300 mM sucrose, 150 mM NaCl, and complete protease inhibitor cocktail (Roche; catalog No. 11836170001). Homogenates were spun at 620 g for 10 min, and Triton X-100 was added to the supernatant to a final concentration of 1%. After incubation for 30 min, a supernatant (designated the total tissue extract) was obtained by centrifugation at 300,000 g until use. Membrane fractions and extracts were prepared from fresh chicken tissues as described (21), except that the extraction buffer contained 1% Triton X-100. The clear supernatant, designated the membrane extract, was treated as described above.

Blotting procedures

For Western blotting of apoA-V and, where indicated, of LR8, extracts were analyzed by one-dimensional 12% SDS-PAGE under reducing conditions and electrophotically transferred to nitrocellulose membranes (Hybond-C Extra; Amersham Biosciences). Non-specific binding sites were blocked with TBS (20 mM Tris-HCl, pH 7.4, and 137 mM NaCl) containing 5% (w/v) nonfat dry milk and 0.1% Tween-20 (blocking buffer) for 1 h at 23°C. ggapoA-V was detected with rabbit anti-ggapoA-V antiserum (1:2,000 dilution) followed by incubation with HRP-conjugated goat anti-rabbit IgG (1:40,000) and development with the enhanced chemiluminescence protocol (Pierce). The sizes of proteins were estimated with a broad-range molecular mass standard (20–250 kDa) from Bio-Rad.

Preparation of chicken lipoproteins

Blood of laying hens was collected in a tube containing EDTA (final concentration, 1 mg/ml) and placed on ice, and plasma was obtained by centrifugation at 4°C. For the preparation of chicken VLDL, the plasma was subjected to ultracentrifugation at 200,000 g for 24 h, and chicken VLDL was recovered from the top. To obtain the total lipoprotein fraction, plasma was subjected to centrifugation at a density of 1.21 g/ml (22). The lipoproteins were dialyzed against 10 mM Tris-HCl, 140 mM NaCl, and 1 mM EDTA, pH 7.4, sterile-filtered, and stored at 4°C. For electrophoretic analysis, aliquots were delipidated in chloroform-methanol (3:1, v/v) and diethyl ether-ethanol (2:1, v/v) at -20°C.

RESULTS

The sequence of XM_417939.2 (National Center for Biotechnology Information; predicted: Gallus gallus, similar to apoA-V, gi:118101988) was used to produce a 1,053 bp cDNA fragment by RT-PCR using RNA from laying hen liver and the primer pair 5’-ATGTCCGTGAGGCTGCGCTTTCTG-3’ (forward) and 5’-TACGGGGCGGTTCGCCGC-3’ (reverse). Comparative genomic sequence analysis confirmed that the chicken APOA5 locus is localized in a gene cluster on chromosome 24 that also contains APOAI and APOA4. The DNA sequences determined from five independent ampiclons were identical, and the predicted precursor protein sequence of 351 amino acids is shown in Fig. 1. The alignment with human (366 residues) and murine (368 residues) apoA-V proteins revealed a high degree of conservation of this gene product from chicken to mammals: identities and similarities (considering conservative replacements) are 42% and 61%, respectively, between chicken and human proteins and 39% and 59%, respectively, between chicken and murine apoA-V; for comparison, human and murine apoA-V are 72% identical and 82% similar. On the other hand, galline apoA-I and apoA-V are only 18% identical and have a similarity of 35%. The ggapoA-V precursor protein is predicted to be cleaved between alanine-23 and arginine-24, a position corresponding exactly to alanine/arginine pairs in the human and murine homologs (Fig. 1). In the center of ggapoA-V, a region rich in positively charged and hydrophobic residues reminiscent of motifs in mammalian apoE and apoB is particularly well conserved. Consensus N-glycosylation sites are absent from all apoA-V proteins analyzed.

Next, the mature protein (328 residues) was expressed as a His6-tagged fusion protein in BL21 cells, purified, and used to generate rabbit antiserum. The antiserum recognized an ~40 kDa plasma protein in hens and roosters; preimmune serum showed no reactivity (Fig. 2). Western blotting revealed the presence of ggapoA-V in the VLDL fraction obtained by ultracentrifugation (d < 1,006 g/ml).
as well as in the resulting bottom fraction (Fig. 2, lane 6); also, the total lipoprotein fraction (floated at d < 1.210 g/ml) contained the protein in significant amounts (data not shown). In addition, ggapoA-V was detected in total protein extracts of liver, small intestine, kidney, brain, and ovarian small white follicles (Fig. 3). Interestingly, the level of immunoreactive protein in the kidney, a very active site of apolipoprotein synthesis in the chicken (23), was among the highest observed (Fig. 3, lane 3).

Next, in our efforts to gain insight into apoA-V action, we directly tested for the binding of chicken apoA-V to LDL receptor relatives (LRs) by ligand blotting (24). As a source of receptor, we used membrane extracts of chicken ovarian follicles, which are enriched in the major oocyte receptor for yolk precursors, termed LR8 (25). The ligand blotting incubation buffer contained a crude extract of BL21 expressing His_{6}-tagged ggapoA-V (Fig. 4, lanes 1–3) or purified ggapoA-V (Fig. 4, lanes 4, 6), and the position of bound ggapoA-V was visualized by immunoblotting with anti-His (lane 6) or anti-ggapoA-V (lanes 1, 2, 4) antibodies. Clearly, both ggapoA-V from the crude bacterial extract and the purified ggapoA-V bound to a 95 kDa protein in the follicle extract that comigrated with, and was immunologically demonstrated to represent, LR8 (Fig. 4, lanes 3, 7). When the incubation contained ggapoA-V plus EDTA, which chelates divalent cations required for LR-ligand interactions, a greatly diminished signal was observed (Fig. 4, lane 2). Figure 4, lane 5 directly demonstrates the binding of RAP, a known paninhibitor of LR-ligand interactions, to LR8, confirming the ligand binding competence of LR8 in the follicle extract.

Accordingly, Fig. 5 shows that GST-RAP very efficiently competes with ggapoA-V for binding sites on LR8 (lane 1 vs. lane 2). Furthermore, when the follicle extract had been subjected to SDS-PAGE under reducing conditions, the binding of ggapoA-V was abolished, demonstrating that the interaction with LR8 required intact disulfide bonds in the receptor, as shown previously for the binding of apoB, apoE, RAP, and clusterin (reviewed in Ref. 12). These experiments confirm that the interaction of ggapoA-V, either in a crude bacterial detergent lysate or in purified form, is specific for a prototype member of the LR gene family and that this binding displays all of the properties

Fig. 3. Detection of ggapoA-V protein in peripheral tissues. Total protein extracts (50 μg per lane) from mature hen liver (lane 1), small intestine (lane 2), kidney (lane 3), brain (lane 4), and ovarian small white follicles (diameter, 3 mm; lane 5) were separated by 12% SDS-PAGE under reducing conditions and analyzed by Western blotting with rabbit anti-ggapoA-V antiserum, as described in Materials and Methods. The positions of migration (kDa) of marker proteins are indicated.

Fig. 4. Recombinant ggapoA-V binds to chicken lipoprotein receptor. Nitrocellulose strips containing SDS-PAGE-separated proteins from ovarian follicle membrane extract were incubated with Triton X-100 extracts obtained from BL21 cells expressing His_{6}-tagged ggapoA-V (lanes 1, 2) or with purified His_{6}-tagged ggapoA-V (lanes 4, 6) in the absence (lane 1) or presence (lane 2) of EDTA or with glutathione S-transferase-receptor-associated protein (GST-RAP; lane 5). The strips were washed and incubated with anti-ggapoA-V antiserum (lanes 1, 2, 4), anti-His antibody (lane 6), or anti-GST antibody (lane 5). LDL receptor relative 8 (LR8) in the ovarian follicle membrane extract was identified by Western blotting with antibody against LR8 (lanes 3, 7). The bound primary antibodies were detected either with HRP-conjugated anti-rabbit IgG or HRP-conjugated anti-mouse IgG and the chemiluminescence detection method, as described in Materials and Methods. The positions of migration (kDa) of marker proteins are indicated.
that characterize the interactions of bona fide ligands with the cysteine-rich ligand binding domains of LRs.

**DISCUSSION**

This study has revealed a novel property of apoA-V, which suggests an additional mechanism for the action of apoA-V in regulating plasma TG levels. As indicated previously (6, 7), apoA-V must be a potent agent despite its low plasma concentration. In addition to the proposed apoA-V-mediated activation of lipolysis by bridging TG-rich lipoproteins and LPL-proteoglycan complexes (26), the possibility that apoA-V may be a ligand for lipoprotein receptors has been raised (7, 8). If such an interaction occurred, it would likely influence directly or indirectly the extent of receptor-mediated clearance of particles generated in lipolytic pathways. In this context, it is of interest that the proportion of lipoprotein-free ggapoA-V appears to be significant (Fig. 2; data not shown) and that this form binds to LRs (Figs. 4, 5). If this holds true for humans, free apoA-V, possibly represented by the exchangeable pool (27), might be a potent TG modulator despite the low concentration of total apoA-V (28, 29). Nilsson et al. (9) reported an interaction of human apoA-V, in both free and lipid-bound form, with LRP and SorLA/LR11, as determined by surface plasmon resonance. They suggested that circulating levels of apoA-V may be low because free apoA-V remains receptor-bound during recycling after endocytosis. Finally, the possibility that lipid-free human wild-type apoA-V exists was demonstrated in a heterozygote whose mutant allele produced truncated apoA-V [Q139X; (30)] and is compatible with the reported solubility of apoA-V [insoluble at >0.1 mg/ml, which is, however, 100- to 1,000-fold greater than even total apoA-V concentrations (31)].

We propose that the regulation of the receptor-modulating activity of apoA-V occurs at the level of its distribution in serum and at the site(s) of clearance, parameters that are related to LR levels, to liver status (1), to apoC-II/C-III ratios, to the apolipoprotein content at the hepatocyte surface (6, 8), and/or to expression levels of proteoglycans (7). Fine-tuned binding of apoA-V to LRs appears to be compatible with the positive correlation between apoA-V and TG levels in human (29) (via competing for binding sites for TG-rich LPs) and, on the other hand, conforms with the severe hypertriglyceridemia and reduced LPL mass and activity of patients with truncated forms of apoA-V (30, 32) (via dysfunction of apoA-V as a ligand for LRs, LPL, and proteoglycans).

These studies in the chicken, which have revealed a novel property of apoA-V, also have new implications and raise new questions. These are concerned with whether or not receptor binding affinity is influenced by the degree of lipid association of ggapoA-V and whether binding is invariably coupled to internalization. Also, because the chicken does not express apoE (33, 34), ggapoA-V may compensate functionally for the absence of this important LR ligand. Finally, delineation of the relevance and role(s) of apoA-V in the kidney, brain, and ovarian follicles may reveal further general insights into apoA-V biology.

This study was supported by the Austrian Science Foundation and the Herzfeldersche Endowment (to W.J.S.).

**REFERENCES**

1. van der Vliet, H. N., M. G. Sammels, A. C. Leegwater, J. H. Levels, P. H. Reitsma, W. Boers, and R. A. Chamuleau. 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. *J. Biol. Chem.* **276**: 44512–44520.

2. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science.* **294**: 169–173.

3. Lai, C. Q., L. D. Parnell, and J. M. Ordovas. 2005. The APOAI/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. *Curr. Opin. Lipidol.* **16**: 153–166.

4. Baroukh, N., E. Bauge, J. Akiyama, J. Chang, V. Afzal, J. C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio. 2004. Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice. *Arterioscler. Thromb. Vasc. Biol.* **24**: 1297–1302.

5. Talmud, P. J., J. A. Cooper, H. Hattori, I. P. Miller, G. J. Miller, and
S. E. Humphries. 2006. The apolipoprotein AV genotype and plasma apolipoprotein AV and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. *Diabetologia* **49**: 2357–2359.

6. Jakel, H., M. Nosek, A. Hellebois-Chapman, J. Frucht-NAjib, and J. C. Fruchtart. 2006. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? *Am. J. Med.* **12**: 2–10.

7. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein AV-heparin interactions: implications for plasma lipoprotein metabolism. *J. Biol. Chem.* **280**: 25385–25387.

8. Grosskopf, I., N. Baroukh, S. J. Lee, Y. Kamari, D. Harats, E. M. Rubin, L. A. Pennacchio, and A. D. Cooper. 2005. Apolipoprotein AV deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. *Arterioscler. Thromb. Vasc. Biol.* **25**: 2573–2579.

9. Nilson, S. K., A. Lookene, J. A. Beckstead, J. Gilemann, R. O. Ryan, and G. Olivecrona. 2007. Apolipoprotein AV interaction with members of the low density lipoprotein receptor gene family. *Biochemistry.* **46**: 3896–3904.

10. Rohlmann, A., M. Gotthardt, R. E. Hammer, and J. Herz. 1998. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. *J. Clin. Invest.* **101**: 689–695.

11. Kanaki, T., H. Bujo, S. Hiroyama, I. Ishii, N. Morisaki, W. J. Schneider, and Y. Saito. 1999. Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions. *Arterioscler. Thromb. Vasc. Biol.* **19**: 2687–2695.

12. Schneider, W. J., J. Nimpf, C. Brandes, and M. Drexl. 1999. The low-density lipoprotein receptor family: genetics, function, and evolution. *Curr. Atheroscler. Rep.* **1**: 113–122.

13. Hengstschläger-Ottnad, E., K. Kuchler, and W. J. Schneider. 1995. Chicken lecithin-cholesterol acyltransferase. Molecular characterization reveals unusual structure and expression pattern. *J. Biol. Chem.* **270**: 26139–26145.

14. Hummel, S., A. Osanger, T. M. Bajari, M. Balasubramani, W. Hafier, J. Nimpf, and W. J. Schneider. 2004. Extracellular matrices of the avian ovarian follicle. Molecular characterization of chicken perlecain. *J. Biol. Chem.* **279**: 23486–23494.

15. Hermann, M., K. A. Lindstedt, R. Foisner, S. Morwald, M. G. Mahon, R. Wandl, W. J. Schneider, and J. Nimpf. 1998. Apolipoprotein A4 production by chicken granulosa cells. *FASEB J.* **12**: 897–903.

16. Steinmetz, A., M. Hermann, J. Nimpf, R. Aebbersold, A. Ducret, R. B. Weinberg, and W. J. Schneider. 1998. Expression and conservation of apolipoprotein AIV in an avian species. *J. Biol. Chem.* **273**: 10543–10549.

17. Attie, A. D., Y. Hamon, A. R. Brooks-Wilson, M. P. Gray-Keller, M. L. MacDonald, V. Rigot, A. Tebon, L. H. Zhang, J. D. Mulligan, R. R. Singaraja, et al. 2002. Identification and functional analysis of a naturally occurring 89K mutation in the ABCA1 gene of the WHAM chicken. *J. Lipid Res.* **43**: 1610–1617.

18. Schneider, W. J., R. Carroll, D. L. Severson, and J. Nimpf. 1990. Apolipoprotein VLDL-II inhibits lipolysis of triglyceride-rich lipoproteins in the laying hen. *J. Lipid Res.* **31**: 507–513.

19. Buo, H., M. Hermann, M. O. Kaderli, L. Jacobsen, S. Sugawara, J. Nimpf, T. Yamamoto, and W. J. Schneider. 1994. Chicken oocyte growth is mediated by an eight ligand binding repeat member of the LDL receptor family. *EMBO J.* **13**: 5165–5175.

20. Herz, J., J. L. Goldstein, D. K. Strickland, Y. K. Ho, and M. S. Brown. 1991. 39kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. *J. Biol. Chem.* **266**: 21232–21238.

21. Stifani, S., R. George, and W. J. Schneider. 1988. Solubilization and characterization of the chicken oocyte vitellogenin receptor. *Biochem. J.* **250**: 467–475.

22. Nimpf, J., R. George, and W. J. Schneider. 1988. Apolipoprotein specificity of the chicken oocyte receptor for low and very low density lipoproteins: lack of recognition of apolipoprotein VLDL-II. *J. Lipid Res.* **29**: 657–667.

23. Tarugi, P., G. Ballarini, B. Pinotti, A. Franchini, E. Ottaviani, and S. Calandria. 1998. Secretion of apoE- and apoA-I-containing lipoproteins by chick kidney. *J. Lipid Res.* **39**: 731–743.

24. Daniel, T. O., W. J. Schneider, J. L. Goldstein, and M. S. Brown. 1983. Visualization of lipoprotein receptors by ligand blotted. *J. Biol. Chem.* **258**: 4606–4611.

25. Bujo, H., K. A. Lindstedt, M. Hermann, L. M. Dalmaj, J. Nimpf, and W. J. Schneider. 1995. Chicken oocytes and somatic cells express different splice variants of a multifunctional receptor. *J. Biol. Chem.* **270**: 23546–23551.

26. Merkel, M., B. Loeßfler, M. Kluger, N. Fahig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. *J. Biol. Chem.* **280**: 21553–21560.

27. Merkel, M., and J. Heeren. 2005. Give me A5 for lipoprotein hydrolysis! *J. Clin. Invest.* **115**: 2694–2696.

28. O’Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodoo, M. D. Kniernam, A. E. Schulze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. *Clin. Chem.* **51**: 351–359.

29. Schaap, F. G., M. C. Nierman, J. F. Berbee, H. Hattori, P. J. Talmud, S. F. Vassens, P. C. Reusen, R. A. Chamuleau, J. A. Kuivenhoven, and A. K. Groen. 2006. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. *J. Lipid Res.* **47**: 2333–2339.

30. Marcais, C., B. Verge, S. Charriere, V. Pruneta, M. Merlin, S. Billon, L. Perrot, J. Drai, A. Sassolas, L. A. Pennacchio, et al. 2005. ApoA5 Q159X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. *J. Clin. Invest.* **115**: 2862–2869.

31. Beckstead, J. A., M. N. Oda, D. D. Martin, T. M. Forte, J. K. Bielicki, T. Berger, R. Luty, C. M. Kay, and R. O. Ryan. 2003. Structure-function studies of human apolipoprotein AV: a regulator of plasma lipid homeostasis. *Biochemistry.* **42**: 9416–9423.

32. Oliva, C. P., P. Tarugi, S. Calandra, L. Pisciotta, A. Bellocchio, S. F. Vaessen, P. C. Rensen, R. A. Chamuleau, J. A. Kuivenhoven, and A. K. Groen. 2006. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. *Atherosclerosis* **188**: 215–217.

33. Baraket, H. A., and R. W. St Clair. 1985. Characterization of plasma lipoproteins of grain- and cholesterol-fed White Carneau and Show Racer pigeons. *J. Lipid Res.* **26**: 1252–1268.

34. Hermier, D., P. Forgez, and M. J. Chapman. 1985. A density gradient study of the lipoprotein and apolipoprotein distribution in the chicken, *Gallus domesticus*. *Biochim. Biophys. Acta.* **836**: 105–118.